Ann: PTX successful immunogenicity testing of OmniCAR, page-87

What resonates with me is the CEO stating (to the effect) that CarT immunotherapy has been a breakthrough in cancer treatment but that with all initial breakthrough technologies there's always inherent issues to overcome. And, for prospective SH, it's about getting in on a trend early and PTX is essentially the next level ahead of the revolution.

PTX is going to address the problems with their OmniCar platform (and hopefully conquer them). PTX is definitely at the next level of immunotherapy... where efficacy and treatment of the most difficult of all cancers (solid tumors) is looking highly promising unlike the way current CarT treatment is performing in this area. PTX seems to have nailed the synergies and agnostic nature that will set its platform apart from its competitors' modalities in this field.

I'm excited over being able to get my teeth into something outside the resource sector. One thing I know from experience, is that biotech can be risky but also very rewarding with the right research. PTX reminds me of Viralytics... it had a single immunotherapy drug that used the common common cold virus to infect and kill cancer, particularly when used in combination with existing Cart treatments. After testing Cavatak with MSD's Keytruda to treat melanoma, prostate, lung and bladder cancerssuccessfully in clinical trials, Merck acquired the tiny ASX co in 2018 for $500 million.

The Merck t/o occurred not long after successful Phase 2 trials saw the SP smashed by over 50%. 60c was the price at the time... and the t/o price $1.75. Needless to say, I was a very happy trooper upon that news and outcome. I've not been able to ascertain the destiny of our wonder drug. Merck undertook further testing in the area of bladder cancer which I believe resulted in equally successful data about a year later. But not heard a peep since.

The trouble with Big Pharma, though, is whether the love of the almighty dollar dictates the withholding of the most effective treatments from commercialisation. Merck don't seem to have commercialised Cavatak from my bit of subsequent research. Disappointing to say the least.

Anyway, we know PTX could have the goods, so let's hope that whoever we may partner with or sell our drugs and/or platform to, does the right thing and commercialises it. Based on VLA's final valuation of half a billion for a company with a solitary drug, surely that hints at PTX, @BigDaniel, with its raft of treatments and the Omni-Car platform having a substantially higher valuation than that...? I'd be thinking at least double if and when say it reaches successful conclusion of Phase 2 trials across the board a couple of years from now. Wishful thinking maybe but....